| HRA010624
(Controlled Access)
|
In this study, we explored the potential of cell-free circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) as a tool for personalizing treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Despite the growing interest in ctDNA as a non-invasive alternative to tissue biopsy for mutational profiling, its clinical application remains underexplored in Chinese NSCLC populations. Through a retrospective analysis of NGS results from 522 Chinese patients diagnosed with stage III or IV NSCLC, we assessed the feasibility of using ctDNA-based NGS to detect mutations and guide targeted therapies. |
